Raymond James analyst Jayson Bedford raised his price target for Tandem Diabetes to $91 from $85, saying that while Q4 results were in-line with consensus, 2020 guidance was roughly 3% ahead of consensus, with upside coming from better U.S. growth. Bedford tells investors in a research note that he continues to believe Tandem has the best therapy for people with type 1 diabetes, and with U.S. pump penetration at less than 20% of insulin users, believes the opportunity for market growth and share gains is large.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here